二肽基肽酶-4抑制剂对2型糖尿病患者血糖和胰岛功能的影响  

Effect of dipeptidyl peptidase-4 inhibitor sitagliptin phosphate on the blood glucose and isletβcell functions of T2DM patients

作　　者：顾丽萍[1] 顾鸣宇[1] 严率[1] 赵立[1] 黄云鸿[1] 彭永德[1] 

机构地区：[1]上海交通大学附属第一人民医院内分泌代谢科,200080

出　　处：《中国糖尿病杂志》2014年第10期883-885,共3页Chinese Journal of Diabetes

基　　金：国家自然科学基金(81070682;81000333);上海市卫生局青年基金(2009Y035)

摘　　要：目的探讨口服降糖药二肽基肽酶-4(DPP-4)抑制剂对T2DM患者的临床疗效及安全性。方法对32例口服降糖药及胰岛素治疗血糖控制不佳的T2DM患者使用DPP-4抑制剂进行12周的治疗观察,测定治疗前后BMI、SBP、DBP、TC、TG、FPG、2hPG、Scr、谷丙转氨酶(AST)、HbA1c、FC-P及2hC-P水平。同时计算胰岛素抵抗指数[HOMA-IR(C-P)]及胰岛β细胞功能指数[HOMA-β(C-P)]。结果 12周后FPG[(7.94±0.52)mmol/L]、2hPG[(12.29±1.07)mmol/L]、HbA1c[(8.44±0.50)%]均较治疗前下降(P<0.01),FC-P水平[(6.52±0.13)pmol/L]、2hC-P水平[(7.83±0.17)pmol/L]及HOMA-β均增加(P<0.01)。研究期间均无严重低血糖事件发生。结论 DPP-4抑制剂可降低T2DM患者FPG、2hPG、HbA1c水平,同时改善胰岛β细胞功能,且无明显不良反应,安全性较好。Objective To evaluate the effect and safety of oral hypoglycemic agent,dipeptidyl peptidase-4 inhibitor,in the treatment of T2DM.Methods Thirty-two patients,with mild to moderate hyperglycemia,were given sitagliptin 100 mg once daily for 12 weeks.The indices including BMI,SBP,DBP,TC,TG,FPG,2 hPG,Scr,AST,HbA1c,FC-P,and two-hour postprandial C-peptide （2 hC-P） before and after the treatment were measured.HOMA-IR （C-P） and HOMA-β （C-P） were calculated.Results The FPG （7.94±0.52） mmol/L,2 hPG （12.29±1.07）mmol/L,and HbA1c （8.44±0.50）％ decreased significantly after the treatment （P＜0.01）.FC-P （6.52±0.13） pmol/L and 2 hC-P （7.83± 0.17） pmol/L and HOMA-β increased significantly （P＜0.01）.There was no severe hypoglycemic episode.Conclusion Dipeptidyl peptidase-4 inhibitor used in combination decreases the level of FPG,2 hPG,and HbA1 c and improves the islet β cell functions.Its effect and safety are good.

关 键 词：糖尿病 2型 二肽基肽酶-4抑制剂 

分 类 号：R587.1[医药卫生—内分泌]